Whitehawk, Biocytogen Launch Global Collaboration for Bispecific Antibody ADC Development
WHWK•Whitehawk Therapeutics and Biocytogen have formed a global collaboration to develop bispecific antibody–drug conjugates. The partnership aims to combine Whitehawk’s bispecific antibody platform with Biocytogen’s ADC development capabilities to advance novel therapeutic candidates toward preclinical milestones.
1. Collaboration Overview
Whitehawk Therapeutics and Biocytogen have entered a worldwide partnership to co-develop next-generation bispecific antibody–drug conjugates (ADCs). The agreement leverages Whitehawk’s expertise in bispecific antibody engineering alongside Biocytogen’s established ADC development infrastructure to identify and progress novel oncology candidates through preclinical evaluation.
